{"id":556510,"date":"2021-08-06T14:38:01","date_gmt":"2021-08-06T14:38:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=556510"},"modified":"2021-08-06T14:38:01","modified_gmt":"2021-08-06T14:38:01","slug":"major-depressive-disorder-market-insight-epidemiology-and-market-forecast-2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/major-depressive-disorder-market-insight-epidemiology-and-market-forecast-2030_556510.html","title":{"rendered":"Major Depressive Disorder Market Insight, Epidemiology And Market Forecast -2030"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Major Depressive Disorder Market Insight, Epidemiology And Market Forecast -2030\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" alt=\"Major Depressive Disorder Market Insight, Epidemiology And Market Forecast -2030\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP      <\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight&#8217;s &#8220;Major Depressive Disorder Market Insights, Epidemiology, and Market Forecast-2030&#8221; report delivers an in-depth understanding of the Major Depressive Disorder, historical and forecasted epidemiology as well as the Major Depressive Disorder market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<\/div>\n<p style=\"text-align: justify;\"><span>What is Major Depressive Disorder?<\/span><\/p>\n<p style=\"text-align: justify;\">Major Depressive Disorder (MDD), also referred as depression, is a serious medical illness that disrupts a person&rsquo;s mood, behavior, thought processes, apart from degrading the physical health.<\/p>\n<p style=\"text-align: justify;\"><span>How Major Depressive Disorder affected population?<\/span><\/p>\n<p style=\"text-align: justify;\"><span>Major Depressive Disorder Epidemiology<\/span><\/p>\n<ul style=\"text-align: justify;\">\n<li>The most prevalent cases of Major Depressive Disorder (MDD) were recorded in the United States.<\/li>\n<li>Among the European 5 countries, France had highest prevalent population of Major Depressive Disorder (MDD), followed by Germany and Spain. On the other hand, the United Kingdom had the lowest prevalent population of Major Depressive Disorder (MDD)<\/li>\n<li>The third most prevalent cases of Major Depressive Disorder (MDD) in 7MM were recorded in Japan.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><span>To know more, request sample pages of&nbsp;<\/span><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/major-depressive-disorder-market\"><span>Major Depressive Disorder Market<\/span><\/a><span>&nbsp;@&nbsp;<\/span><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/major-depressive-disorder-market\"><span>https:\/\/www.delveinsight.com\/report-store\/major-depressive-disorder-market<\/span><\/a><\/p>\n<p style=\"text-align: justify;\"><span>Major Depressive Disorder Market Outlook<\/span><\/p>\n<p style=\"text-align: justify;\">The various major American and European guidelines for the treatment of depression provide similar basic principles of treatment, which include individualizing the treatment plan, preparing the patient for potential long-term treatment, providing measurement-based care, and treating to remission.<\/p>\n<p style=\"text-align: justify;\">The new evidence-based guideline summarizes recommendations on the use of antidepressants and other drug therapies; psychotherapy, including cognitive behavior therapy; and Electroconvulsive Therapy (ECT).<\/p>\n<p style=\"text-align: justify;\">Apart from therapies, companies are also focussed on the development of technologies that could further assist in the better management of the disease. BrainsWay&rsquo;s Deep TMS received FDA clearance in 2018 to treat MDD. Deep TMS works by utilizing a magnetic field that manages to directly reach wider and deeper brain regions, regulating the neural activity of brain structures related to depression &ndash; specifically the dorsolateral prefrontal cortex (DLPFC).<\/p>\n<p style=\"text-align: justify;\"><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter wp-image-331147 size-full\" src=\"https:\/\/dailyresearchsheets.com\/wp-content\/uploads\/2021\/07\/Major-Depressive-Disorder.jpg\" alt=\"Major-Depressive-Disorder\" width=\"750\" height=\"410\" \/><\/p>\n<p style=\"text-align: justify;\"><span>What are the Major Depressive Disorder Market Drivers?<\/span><\/p>\n<p style=\"text-align: justify;\"><span>Introduction of new pathway, increasing awareness on depression, and increasing spending on branded drugs<\/span>&nbsp;are the present Major Depressive Disorder market drivers.<\/p>\n<p style=\"text-align: justify;\"><span>What are the Major Depressive Disorder Market Barriers?<\/span><\/p>\n<p style=\"text-align: justify;\"><span>Challenges in diagnoses, economic burden, and generic products&nbsp;<\/span>are the Major Depressive Disorder market barriers.<\/p>\n<p style=\"text-align: justify;\"><span>Which are the leading companies in Major Depressive Disorder market?<\/span><\/p>\n<p style=\"text-align: justify;\">The emerging treatment options in&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/major-depressive-disorder-market\"><span>Major Depressive Disorder Market Landscape<\/span><\/a>&nbsp;aim to improve the responses which are inadequate with respect to standard antidepressant therapies. Companies such as&nbsp;<span>Axsome Therapeutics, SAGE Therapeutics, J&amp;J\/ Minerva Neurosciences, Intra-Cellular Therapies,&nbsp;<\/span>and others are developing the therapies to transform the Major Depressive Disorder treatment scenario.<\/p>\n<p style=\"text-align: justify;\"><span>Table of contents<\/span><\/p>\n<p style=\"text-align: justify;\"><span>1. Key Insights<\/span><\/p>\n<p style=\"text-align: justify;\"><span>2. Executive Summary of Major Depressive Disorder<\/span><\/p>\n<p style=\"text-align: justify;\"><span>3. Competitive Intelligence Analysis for Major Depressive Disorder<\/span><\/p>\n<p style=\"text-align: justify;\"><span>4. Major Depressive Disorder: Market Overview at a Glance<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">4.1. Major Depressive Disorder Total Market Share (%) Distribution in 2017<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">4.2. Major Depressive Disorder Total Market Share (%) Distribution in 2030<\/p>\n<p style=\"text-align: justify;\"><span>5. Major Depressive Disorder: Disease Background and Overview<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5.1. Introduction<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5.2. Sign and Symptoms<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5.3. Pathophysiology<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5.4. Risk Factors<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5.5. Diagnosis<\/p>\n<p style=\"text-align: justify;\"><span>6. Patient Journey<\/span><\/p>\n<p style=\"text-align: justify;\"><span>7. Major Depressive Disorder Epidemiology and Patient Population<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">7.1. Epidemiology Key Findings<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">7.2. Assumptions and Rationale: 7MM<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">7.3. Epidemiology Scenario: 7MM<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">7.3.1. Major Depressive Disorder Epidemiology Scenario in the 7MM (2017-2030)<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">7.4. United States Epidemiology<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">7.4.1. Major Depressive Disorder Epidemiology Scenario in the United States (2017-2030)<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">7.5. EU-5 Country-wise Epidemiology<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">7.5.1. Germany Epidemiology<\/p>\n<p class=\"ql-indent-3\" style=\"text-align: justify;\">7.5.1.1. Major Depressive Disorder Epidemiology Scenario in Germany (2017-2030)<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">7.5.2. France Epidemiology<\/p>\n<p class=\"ql-indent-3\" style=\"text-align: justify;\">7.5.2.1. Major Depressive Disorder Epidemiology Scenario in France (2017-2030)<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">7.5.3. Italy Epidemiology<\/p>\n<p class=\"ql-indent-3\" style=\"text-align: justify;\">7.5.3.1. Major Depressive Disorder Epidemiology Scenario in Italy (2017-2030)<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">7.5.4. Spain Epidemiology<\/p>\n<p class=\"ql-indent-3\" style=\"text-align: justify;\">7.5.4.1. Major Depressive Disorder Epidemiology Scenario in Spain (2017-2030)<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">7.5.5. United Kingdom Epidemiology<\/p>\n<p class=\"ql-indent-3\" style=\"text-align: justify;\">7.5.5.1. Major Depressive Disorder Epidemiology Scenario in the United Kingdom (2017-2030)<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">7.5.6. Japan Epidemiology<\/p>\n<p class=\"ql-indent-3\" style=\"text-align: justify;\">7.5.6.1. Major Depressive Disorder Epidemiology Scenario in Japan (2017-2030)<\/p>\n<p style=\"text-align: justify;\"><span>8. Treatment Algorithm, Current Treatment, and Medical Practices<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">8.1. Major Depressive Disorder Treatment and Management<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">8.2. Major Depressive Disorder Treatment Algorithm<\/p>\n<p style=\"text-align: justify;\"><span>9. Unmet Needs<\/span><\/p>\n<p style=\"text-align: justify;\"><span>10. Key Endpoints of Major Depressive Disorder Treatment<\/span><\/p>\n<p style=\"text-align: justify;\"><span>11. Marketed Products<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">11.1. List of Marketed Products in the 7MM<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">11.2. Drug Name: Company Name<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">11.2.1. Product Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">11.2.2. Regulatory Milestones<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">11.2.3. Other Developmental Activities<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">11.2.4. Pivotal Clinical Trials<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">11.2.5. Summary of Pivotal Clinical Trial<\/p>\n<p style=\"text-align: justify;\">List to be continued in report<\/p>\n<p style=\"text-align: justify;\"><span>12. Emerging Therapies<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">12.1. Key Cross<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">12.2. Drug Name: Company Name<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">12.2.1. Product Description<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">12.2.2. Other Developmental Activities<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">12.2.3. Clinical Development<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">12.2.4. Safety and Efficacy<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">12.2.5. Product Profile<\/p>\n<p style=\"text-align: justify;\">List to be continued in report<\/p>\n<p style=\"text-align: justify;\"><span>13. Major Depressive Disorder: Seven Major Market Analysis<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">13.1. Key Findings<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">13.2. Major Depressive Disorder Market Size in 7MM<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">13.3. Major Depressive Disorder Market Size by Therapies in the 7MM<\/p>\n<p style=\"text-align: justify;\"><span>14. Attribute analysis<\/span><\/p>\n<p style=\"text-align: justify;\"><span>15. 7MM: Market Outlook<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">15.1. United States: Market Size<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.1.1. Major Depressive Disorder Total Market Size in the United States<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.1.2. Major Depressive Disorder Market Size by Therapies in the United States<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">15.2. EU-5 countries: Market Size and Outlook<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">15.3. Germany Market Size<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.3.1. Major Depressive Disorder Total Market Size in Germany<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.3.2. Major Depressive Disorder Market Size by Therapies in Germany<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">15.4. France Market Size<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.4.1. Major Depressive Disorder Total Market Size in France<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.4.2. Major Depressive Disorder Market Size by Therapies in France<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">15.5. Italy Market Size<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.5.1. Major Depressive Disorder Total Market Size in Italy<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.5.2. Major Depressive Disorder Market Size by Therapies in Italy<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">15.6. Spain Market Size<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.6.1. Major Depressive Disorder Total Market Size in Spain<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.6.2. Major Depressive Disorder Market Size by Therapies in Spain<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">15.7. United Kingdom Market Size<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.7.1. Major Depressive Disorder Total Market Size in the United Kingdom<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.7.2. Major Depressive Disorder Market Size by Therapies in the United Kingdom<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">15.8. Japan Market Outlook<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.8.1. Japan Market Size<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.8.2. Major Depressive Disorder Total Market Size in Japan<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.8.3. Major Depressive Disorder Market Size by Therapies in Japan<\/p>\n<p style=\"text-align: justify;\"><span>16. Access and Reimbursement Overview of Major Depressive Disorder<\/span><\/p>\n<p style=\"text-align: justify;\"><span>17. KOL Views<\/span><\/p>\n<p style=\"text-align: justify;\"><span>18. Market Drivers<\/span><\/p>\n<p style=\"text-align: justify;\"><span>19. Market Barriers<\/span><\/p>\n<p style=\"text-align: justify;\"><span>20. Appendix<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">20.1. Bibliography<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">20.2. Report Methodology<\/p>\n<p style=\"text-align: justify;\"><span>21. DelveInsight Capabilities<\/span><\/p>\n<p style=\"text-align: justify;\"><span>22. Disclaimer<\/span><\/p>\n<p style=\"text-align: justify;\"><span>23. About DelveInsight<\/span><\/p>\n<p style=\"text-align: justify;\"><span>Request sample pages for more information on&nbsp;<\/span><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/major-depressive-disorder-market\"><span>Major Depressive Disorder Market<\/span><\/a><span>&nbsp;@&nbsp;<\/span><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/major-depressive-disorder-market\"><span>https:\/\/www.delveinsight.com\/sample-request\/major-depressive-disorder-market<\/span><\/a><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56407.html\" rel=\"nofollow\">DelveInsight<\/a><br \/><strong>Contact Person:<\/strong> Priya Maurya<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=major-depressive-disorder-market-insight-epidemiology-and-market-forecast-2030\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 09650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=major-depressive-disorder-market-insight-epidemiology-and-market-forecast-2030\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight&#8217;s &#8220;Major Depressive Disorder Market Insights, Epidemiology, and Market Forecast-2030&#8221; report delivers an in-depth understanding of the Major Depressive Disorder, historical and forecasted epidemiology as well as the Major Depressive Disorder market trends in the United &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/major-depressive-disorder-market-insight-epidemiology-and-market-forecast-2030_556510.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[406,423,420,403,404],"tags":[],"class_list":["post-556510","post","type-post","status-publish","format-standard","hentry","category-Pharmaceuticals-Biotech","category-Professional-Services","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/556510","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=556510"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/556510\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=556510"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=556510"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=556510"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}